MK-434

MK-434
Clinical data
Other names	MK-0434; 17β-Benzoyl-4-aza-5α-androst-1-en-3-one
Routes of; administration	By mouth
Drug class	5α-Reductase inhibitor
Identifiers
	IUPAC name (1S,3aS,3bS,5aR,9aR,9bS,11aS)-1-Benzoyl-9a,11a-dimethyl-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinolin-7-one;
CAS Number	134067-56-4;
PubChem CID	131705;
ChemSpider	116366;
UNII	J5DR1P0IKK;
Chemical and physical data
Formula	C25H31NO2
Molar mass	377.528 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)C4=CC=CC=C4)CC[C@@H]5[C@@]3(C=CC(=O)N5)C;
	InChI InChI=1S/C25H31NO2/c1-24-14-12-19-17(8-11-21-25(19,2)15-13-22(27)26-21)18(24)9-10-20(24)23(28)16-6-4-3-5-7-16/h3-7,13,15,17-21H,8-12,14H2,1-2H3,(H,26,27)/t17-,18-,19-,20+,21+,24-,25+/m0/s1; Key:ZYTQEOWFSVTRLX-QKONGSNMSA-N;

MK-434 is a 5α-reductase inhibitor which was under development in the 1990s by Merck & Co for the treatment of a variety of androgen-dependent conditions including benign prostatic hyperplasia, prostate cancer, pattern hair loss, excessive hair growth, acne, and seborrhea but was never marketed.^[1]^[3]^[2] It acts as a selective inhibitor of 5α-reductase type 2.^[2]^[3]^[4] The drug has been found to decrease circulating dihydrotestosterone levels by a maximum of approximately 50% in men.^[2]^[3] MK-434 is a synthetic 4-azasteroid and is structurally related to other 5α-reductase inhibitors like finasteride.^[3]

References

^ ^a ^b https://adisinsight.springer.com/drugs/800005411
^ ^a ^b ^c ^d Van Hecken A, Depré M, Schwartz JI, Tjandramaga TB, Winchell GA, De Lepeleire I, Ng J, De Schepper PJ (1994). "Plasma concentrations and effect on testosterone metabolism after single doses of MK-0434, a steroid 5 alpha-reductase inhibitor, in healthy subjects". Eur. J. Clin. Pharmacol. 46 (2): 123–6. doi:10.1007/bf00199874. PMID 8039530.
^ ^a ^b ^c ^d Chen W, Zouboulis CC, Orfanos CE (1996). "The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders". Dermatology (Basel). 193 (3): 177–84. doi:10.1159/000246242. PMID 8944337.
^ Cooke GM, Pothier F, Murphy BD (March 1997). "The effects of progesterone, 4,16-androstadien-3-one and MK-434 on the kinetics of pig testis microsomal testosterone-4-ene-5alpha-reductase activity". J. Steroid Biochem. Mol. Biol. 60 (5–6): 353–9. doi:10.1016/s0960-0760(96)00223-3. PMID 9219928.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

This dermatologic drug article is a stub. You can help Wikipedia by expanding it.